Brain-Derived Neurotrophic Factor Gene Val66Met Polymorphism Is a Risk Factor for Attention-Deficit Hyperactivity Disorder in a Turkish Sample

Onder Ozturk1, Burge Kabukcu Basay1, Ahmet Buber1, Omer Basay1, Huseyin Alacam2, Ali Bacanlı3, Şenay Görücü Yılmaz4, Mehmet Emin Erdal5, Hasan Herken2,5, and Eyup Sabri Ercan6

1Child and Adolescent Psychiatry Department, Pamukkale University Medical Faculty, Denizli, Turkey
2Psychiatry Department, Pamukkale University Medical Faculty, Denizli, Turkey
3Child and Adolescent Psychiatry Polyclinic, Children Hospital, Gaziantep, Turkey
4Department of Nutritions and Dietetics, Faculty of Healthy Science, University of Gaziantep, Gaziantep, Turkey
5Medical Biology and Genetics Department, Mersin University Medical Faculty, Mersin, Turkey
6Child and Adolescent Psychiatry Department, Ege University Medical Faculty, Izmir, Turkey

Objective Attention-deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder that negatively affects different areas of life. We aimed to evaluate the associations between the Val66Met polymorphism of brain-derived neurotrophic factor (BDNF) and ADHD and to assess the effect of the BDNF polymorphism on the neurocognitive profile and clinical symptomatology in ADHD.

Methods Two hundred one ADHD cases and 99 typically developing subjects (TD) between the ages of 8 and 15 years were involved in the study. All subjects were evaluated using a complete neuropsychological battery, Child Behavior Checklist, the Teacher’s Report Form (TRF) and the DSM-IV Disruptive Behavior Disorders Rating Scale-teacher and parent forms.

Results The GG genotype was significantly more frequent in the patients with ADHD than in the TD controls, and the GG genotype was also significantly more frequent in the ADHD-combined (ADHD-C) subtype patients than in the TDs. However, there were no significant associations of the BDNF polymorphism with the ADHD subtypes or neurocognitive profiles of the patients. The teacher-assessed hyperactivity and inattention symptom count and the total score were higher, and the appropriately behaving subtest score of the TRF was lower in the GG genotypes than in the GA and AA (i.e., the A-containing) genotypes.

Conclusion We found a positive association between the BDNF gene Val66Met polymorphism and ADHD, and this association was observed specifically in the ADHD-C subtype and not the ADHD-predominantly inattentive subtype. Our findings support that the Val66Met polymorphism of BDNF gene might be involved in the pathogenesis of ADHD. Furthermore Val66Met polymorphism of BDNF gene may be more closely associated with hyperactivity rather than inattention.

Key Words Attention-deficit hyperactivity disorder, Brain-derived neurotrophic factor, Gene polymorphism.
Polymorphisms of the human BDNF gene, which is located on chromosome 11p13, have been studied in several psychiatric disorders. The most frequent is the Val66Met (rs6265) guanine (G)-to-adenine (A) single-nucleotide polymorphism (SNP) at nucleotide 196 that results in an amino acid substitution of methionine (Met) for valine (Val). This polymorphism impairs the packaging of proBDNF and results in reduced depolarization-induced secretion of BDNF from neurosecretory cells and cortical neurons. However, in the same study, the authors showed that the constitutive secretion of mature BDNF is not affected by this polymorphism and that the basal release of BDNF continues. The Val (G) allele of the Val66Met polymorphism has been reported to be associated with bipolar disorder and schizophrenia in previous studies. Additionally, the Met allele of the Val66Met polymorphism has been reported to be associated with the restrictive type of anorexia nervosa. Sen et al. reported that the Met allele has a protective effect in depression.

Previous studies have reported inconsistent results regarding the relationship between the BDNF gene and ADHD. Some of the studies have reported a positive association between the Val66Met polymorphism of BDNF and ADHD. One of these studies was conducted by Lanktree et al. who reported a positive association of the Val allele with ADHD in adult patients. In another study that consisted of a family based-sample of 341 ADHD probands also found a relationship between the Val allele and ADHD. In contrast to these results, some studies have reported no association between the BDNF Val66Met polymorphism and ADHD.

Studies of the cognitions related to ADHD have shown that ADHD children often perform poorly on tasks of working memory and exhibit impairments in spatial and verbal components. Lee et al. reported no association between BDNF alleles and working memory abilities in their sample of ADHD families. Mice with an inactivated BDNF gene have exhibit significantly more locomotor activity when stressed than normal mice. Additionally, animal studies have revealed that BDNF is critical for learning and working memory.

In the present study, we hypothesized that this BDNF gene polymorphism might be involved in the pathogenesis of ADHD and influence clinical presentations including neurocognition and symptoms. Therefore, we aimed to evaluate the associations between the Val66Met polymorphism of the BDNF gene and ADHD and to assess the effects of this BDNF polymorphism on the neurocognitive profile and clinical symptomatology of ADHD.

METHODS

Study design

The present study included 201 ADHD subjects [101 ADHD-combined (ADHD-C) and 100 ADHD-predominantly inattentive type (ADHD-I)] and 99 typically developing (TD) subjects aged 8 to 15 years who were consecutively assessed in the child and adolescent psychiatry clinic of Ege University from December 2011 to March 2013. The parents provided written informed consent. The Ethics Committee of Pamukkale University approved the study protocol.

Participants

The inclusion criteria for both the ADHD and TD subjects were the following: 1) an estimated intelligence quotient (IQ) greater than 80, 2) no history of head injury with loss of consciousness, 3) no neurological or other serious medical disease, 4) no prior use of stimulants, and 5) no use of psychotropic medication within the last six months. For the ADHD subjects, the additional criterion of a lack of history of any psychiatric disorder other than oppositional defiant disorder (ODD) was also included. For the TD controls, the additional criterion of a lack of any psychiatric disorder was included.

Diagnostic procedures

Initially, the families and teachers completed the Child Behavior Checklist (CBCL), the Teacher’s Report Form (TRF), and the DSM-IV Disruptive Behavior Disorders Rating Scale—teacher and parent forms. The subjects with inattentive scores that were 1 SD greater than the age norms for these scales were invited to participate in the diagnostic portion of the study. This procedure was performed to guarantee that the inattentive symptoms were adequately represented in all of the ADHD types assessed. Thereafter, a semi-structured interview (i.e., the Kiddie-Schedule for Affective Disorders and Schizophrenia, present and life time version—K-SADS-PL) was applied to parents by a senior child psychiatry resident. Additionally, we assessed the participants estimated IQs using the vocabulary and block design subtests of the WISC-R.

Two experienced child psychiatrists who were blinded to the first diagnostic assessment conducted confirmatory second diagnostic interviews with the participants with positive ADHD diagnoses in the first KSDAS-PL interview. The parents and subjects were also interviewed according to the K-SADS-PL. “A best estimate procedure” was used to determine the final diagnoses. Three subjects refused to attend the second diagnostic interview, and disagreements between interviews regarding the ADHD types/comorbid diagnoses occurred in 10 cases. Thirteen subjects were excluded from

Participants

The inclusion criteria for both the ADHD and TD subjects were the following: 1) an estimated intelligence quotient (IQ) greater than 80, 2) no history of head injury with loss of consciousness, 3) no neurological or other serious medical disease, 4) no prior use of stimulants, and 5) no use of psychotropic medication within the last six months. For the ADHD subjects, the additional criterion of a lack of history of any psychiatric disorder other than oppositional defiant disorder (ODD) was also included. For the TD controls, the additional criterion of a lack of any psychiatric disorder was included.

Diagnostic procedures

Initially, the families and teachers completed the Child Behavior Checklist (CBCL), the Teacher’s Report Form (TRF), and the DSM-IV Disruptive Behavior Disorders Rating Scale—teacher and parent forms. The subjects with inattentive scores that were 1 SD greater than the age norms for these scales were invited to participate in the diagnostic portion of the study. This procedure was performed to guarantee that the inattentive symptoms were adequately represented in all of the ADHD types assessed. Thereafter, a semi-structured interview (i.e., the Kiddie-Schedule for Affective Disorders and Schizophrenia, present and life time version—K-SADS-PL) was applied to parents by a senior child psychiatry resident. Additionally, we assessed the participants estimated IQs using the vocabulary and block design subtests of the WISC-R.

Two experienced child psychiatrists who were blinded to the first diagnostic assessment conducted confirmatory second diagnostic interviews with the participants with positive ADHD diagnoses in the first KSDAS-PL interview. The parents and subjects were also interviewed according to the K-SADS-PL. “A best estimate procedure” was used to determine the final diagnoses. Three subjects refused to attend the second diagnostic interview, and disagreements between interviews regarding the ADHD types/comorbid diagnoses occurred in 10 cases. Thirteen subjects were excluded from

Participants

The inclusion criteria for both the ADHD and TD subjects were the following: 1) an estimated intelligence quotient (IQ) greater than 80, 2) no history of head injury with loss of consciousness, 3) no neurological or other serious medical disease, 4) no prior use of stimulants, and 5) no use of psychotropic medication within the last six months. For the ADHD subjects, the additional criterion of a lack of history of any psychiatric disorder other than oppositional defiant disorder (ODD) was also included. For the TD controls, the additional criterion of a lack of any psychiatric disorder was included.

Diagnostic procedures

Initially, the families and teachers completed the Child Behavior Checklist (CBCL), the Teacher’s Report Form (TRF), and the DSM-IV Disruptive Behavior Disorders Rating Scale—teacher and parent forms. The subjects with inattentive scores that were 1 SD greater than the age norms for these scales were invited to participate in the diagnostic portion of the study. This procedure was performed to guarantee that the inattentive symptoms were adequately represented in all of the ADHD types assessed. Thereafter, a semi-structured interview (i.e., the Kiddie-Schedule for Affective Disorders and Schizophrenia, present and life time version—K-SADS-PL) was applied to parents by a senior child psychiatry resident. Additionally, we assessed the participants estimated IQs using the vocabulary and block design subtests of the WISC-R.

Two experienced child psychiatrists who were blinded to the first diagnostic assessment conducted confirmatory second diagnostic interviews with the participants with positive ADHD diagnoses in the first KSDAS-PL interview. The parents and subjects were also interviewed according to the K-SADS-PL. “A best estimate procedure” was used to determine the final diagnoses. Three subjects refused to attend the second diagnostic interview, and disagreements between interviews regarding the ADHD types/comorbid diagnoses occurred in 10 cases. Thirteen subjects were excluded from
the second diagnostic part of the study. Unrelated healthy controls were also recruited from the same community and were matched as well possible to the ADHD patients in terms of age and gender. The exact same diagnostic procedure was applied for the assessments of the controls. However, we required that the TD subjects exhibited inattentive scores that were one standard deviation below the means for the child’s age on the CBCL, TRF, and ADHD-RS-IV scales. Consequently, 101 ADHD-C, 100 ADHD-I type and 99 TD subjects were included in the study.

Neuropsychological evaluation

All cases in the study were assessed using a standardized neuropsychological battery (CNS-VS) that included tests addressing the neuropsychological constructs known to be associated with ADHD. The battery included tests that measured verbal and visual memory, finger tapping, digit symbol coding, the Stroop test, a test of shifting attention and the continuous performance test (CPT). Six main scores, including the neurocognitive index, total memory, reaction time, complex attention, cognitive flexibility, and psychomotor speed, were obtained.30

DNA extraction and genotype determination

DNA was extracted from saliva samples for genotyping. Genotypes were determined using a TaqMan™ fluorogenic 5’-nuclease assay with TaqMan Probes. All reactions were carried out following the manufacturer’s protocol. Primer Express 3.0 (Applied Biosystems) was used to design both the PCR primers and the TaqMan probes. For BDNF Gene Val66Met (rs6265) polymorphisms, custom made primers and probes are as follows: Forward Primer 5’-AGGCAGGTTCA AGAGGCTTGA-3’, Reverse Primer 5’-TTCTGGTCCTCAT CCAACAGCT-3’, Probe G: 5’-Y akima Yellow-TGA(pdC) A(pdC)TTT(pdC)GAA(pdC)ACGTGATA-BHQ-1-3’, Probe A: 5’-FAM-TGA(pdC)A(pdC)TTT(pdC)GAA(pdC)A(pdC) ATGATA-BHQ-1-3’. Single nucleotide polymorphism amplification assays were performed according to the manufacturer’s instructions. In brief, 25 μL of reaction solution containing 30 ng of DNA was mixed with 12.5 μL of 2X TaqMan Universal PCR Master Mix (Applied Biosystems) and 900 nmol of each primer, 200 nmol of each probe. Reaction conditions consisted of preincubation at 60°C for 1 minute and at 95°C for 10 minute, followed by 40 cycles at 95°C for 15 second and at 60°C for 1 minute. Amplifications and analysis were performed in an ABI Prism 7500 Real-Time PCR System (Applied Biosystems), using the SDS 2.0.6 software for allelic discrimination (Applied Biosystems).

Statistical analyses

The data analyses were performed using the statistical package for the SPSS 17.0 version for PC, and p-values <0.05 were considered statistically significant. Chi-square tests were applied to the categorical variables, and t-tests were applied to the continuous variables for the genotype group comparisons. We performed the multivariate analysis of variance (MANOVA) by assigning the age and gender as covariates to control the effects of these parameters on ADHD-related symptoms. Post-hoc comparisons were carried out using Bonferroni correction and lower than 0.025 p values were accepted as statistically significant for MANOVA because of the presence of two comparison genotype groups.

RESULTS

Two hundred and one patients with ADHD and 99 TD subject were involved the present study. The mean age of the ADHD group was 10.78±2.01 years, and the mean age of the TD group was 10.73±1.92 years. There was no difference in mean age (t=-0.190, p=0.85) between the groups. Although male predominance was provided in both groups of ADHD and TD, there was a significant difference between the patients and TD groups in terms of gender distribution. Sociodemographic and clinical characteristic of the participants were shown in Table 1.

Genetic assessments

The genotype determinations revealed that only 10 subjects (3.3%) among both the ADHD and TD groups had the AA genotype. Therefore, the sample was grouped into GG genotypes and A-containing (GA+AA) genotypes (Table 2). The data analyses revealed significant differences in the genotypic frequency distributions of the Val66Met polymorphism between the ADHD and TD groups. The GG genotype was significantly more frequent among the patients with ADHD than the TD participants (χ²=6.16, p=0.017). Additionally, the genotype frequency distributions of Val66Met polymorphism between the TD groups, ADHD-C subtype and ADHD-I subtype groups were found to be significantly different (χ²=6.16, p=0.046). The GG genotype was significantly more frequent in the ADHD-C group than the TD group. However, the frequency distributions of the GG genotype and A-containing genotypes between the subtypes of ADHD did not differ (Table 2).

Assessments of ADHD-related symptoms

In our study, the teacher-rated hyperactivity and inattention symptom counts and total scores were higher among the GG genotype group than the A-containing genotype group (p=0.031, p=0.025). Regarding the CBCL scores, there were
no significant differences between the Val66Met polymorphism subgroups. However, the appropriate behavior score of the TRF was significantly lower in the GG genotype group than the A-containing genotypes group (p=0.031) (Table 3).

When we performed the multivariate analysis of variance (MANOVA) by assigning the age and gender as covariates to control the effects of these parameters on the ADHD-related symptoms, and we found that the appropriate behavior score of the TRF remained to be statistically significantly different between the polymorphism groups in patients with ADHD (λ=.957, F=2.92, p=0.009) (Table 3).

**DISCUSSION**

In the present study, we found a positive association between the BDNF gene Val66Met SNP polymorphism and ADHD that the GG genotype was more frequent in the patients with ADHD and the ADHD-C subtype than in the TD group. BDNF is a member of the neurotrophins family that has a crucial role in neuronal developmental process, neuroplasticity and neuronal function. Thus investigation of effects of BDNF gene polymorphism on ADHD which is a neurodevelopmental disorder is great importance. The Val66Met polymorphism of BDNF can affect the intracellular trafficking and can reduce depolarization-induced secretion of the BDNF. However, Chen et al. reported that the mature BDNF is not affected by the polymorphism and its basal release continues. The neuropsychiatric studies suggested that the levels of circulating BDNF which is reflect the level of brain-tissue BDNF was effected by the polymorphism. Reduced BDNF levels were reported in Met carriers patients with de-
BDNF Is a Risk Factor for ADHD

Table 3. Comparison of genotype groups in terms of symptoms and neuropsychological findings in patients

|                      | GG genotype mean/SD | GA, AA genotype mean/SD | p*  | p†  | Group comparison         |
|----------------------|---------------------|-------------------------|-----|-----|---------------------------|
| **Attention deficit, hyperactivity symptoms score** |                     |                         |     |     |                           |
| Teacher hyperactivity and inattention symptom count | 11.1±4.3            | 9.5±4.7                 | 0.03*| 0.08| GG>GA, AA                 |
| Teacher hyperactivity and inattention total score   | 25.8±11.2           | 21.7±11.4               | 0.02*| 0.07| GG>GA, AA                 |
| Parent hyperactivity and inattention symptom count  | 10.8±4.2            | 11.0±4.3                | 0.74 |     |                           |
| Parent hyperactivity and inattention total score    | 25.1±10.7           | 26.3±11.8               | 0.52 |     |                           |
| **Child Behavior Checklist (CBCL)**                 |                     |                         |     |     |                           |
| Internalizing total score                            | 58.3±11.0           | 60.0±10.9               | 0.33 |     |                           |
| Externalizing total score                             | 56.1±11.4           | 56.3±11.0               | 0.95 |     |                           |
| Total behavior problems s.                           | 59.8±10.0           | 60.5±11.0               | 0.70 |     |                           |
| **Teacher’s Report Form (TRF)**                      |                     |                         |     |     |                           |
| Behaving appropriately                               | 46.1±7.9            | 49.9±11.6               | 0.03*| 0.009†| GG<GA, AA                |
| Internalizing total score                             | 57.9±8.7            | 57.5±9.0                | 0.76 |     |                           |
| Externalizing total score                             | 54.7±9.3            | 54.7±9.6                | 0.98 |     |                           |
| Total behavior problems s.                           | 56.9±9.2            | 55.9±8.3                | 0.48 |     |                           |
| **Neuropsychological battery (CNS-VS)**              |                     |                         |     |     |                           |
| Total memory score                                    | 85.3±21.2           | 84.5±22.6               | 0.83 |     |                           |
| Reaction time score                                   | 73.7±25.0           | 74.1±28.9               | 0.91 |     |                           |
| Complex attention score                               | 77.1±20.2           | 78.0±18.5               | 0.76 |     |                           |
| Cognitive flexibility score                           | 90.9±17.7           | 93.7±17.6               | 0.22 |     |                           |
| Psychomotor speed score                               | 84.9±18.0           | 85.4±17.7               | 0.86 |     |                           |
| Neurocognitive index score                            | 81.1±12.0           | 81.6±12.8               | 0.78 |     |                           |

*independent simples t-test, statistically significance p<0.05, †multivariate analysis of variance (MANOVA) by assigning the age and gender as covariates (Post-hoc comparisons were carried out using Bonferroni correction and less than 0.025 p values were accepted as statistically significant)

pressure33 and schizophrenia.34 Conversely, studies demonstrated that the healthy human with Met allele carriers have increased circulating BDNF levels.35,36 Li et al.37 indicated that the females who were Met/Met genotype carriers with ADHD had a tendency of increased plasma BDNF levels than Val allele carriers however the difference was not statistically significant. Taken together these data and our result, it may be suggested that the Val allele may contribute to pathogenesis of ADHD.

The relationship between ADHD and the BDNF gene has been investigated in many studies. In accordance with our findings, Kent et al.16 reported a positive association with the Val (G) allele, particularly when this allele is paternally transmitted, in children with ADHD. Similarly, Aureli et al.37 reported that the G allele of the Val66Met polymorphism is significantly associated with ADHD. In another study conducted by Li et al.,38 a higher frequency of the Val allele was found in females with ADHD than in controls. Another study conducted by Lanktree et al.,15 which has currently only been reported in abstract form, described evidence for the involvement of the Val allele of the Val66Met polymorphism in both case control and trio analyses of adult ADHD patients. In light of these results, it may be suggested that there is a positive association between the BDNF polymorphism and ADHD and moreover that this association is more prominent in terms of hyperactivity than inattention. Furthermore, we speculated that the Val allele of the Val66Met polymorphism is a risk factor for ADHD. Conversely, in some previous studies, no evidence of an association between the Val66Met polymorphism and ADHD has been found.17-19,39,40 These contradictory findings may be due to genetic and clinical heterogeneity, the use of different diagnostic practices, differences of in the ADHD subtype distributions across the studies, differences in comorbidities, and the insufficient sample sizes of
the studies.\textsuperscript{46} It is possible that the above mentioned reasons have masked a real association between this disorder and the BDNF gene polymorphism. Additionally, epigenetic factors or mechanisms, such as environmental factors, abnormal imprinting of the genes, and neuroanatomically tissue-specific expression patterns, might affect the pathogenesis of ADHD.\textsuperscript{48} A better understanding of the relationships of variations in genes, such as BDNF, with the pathogenesis of ADHD may require analyses of gene-gene and gene-environment interactions.

The distributions of the Val66Met polymorphism did not differ between the ADHD-C and ADHD-I subtypes in our study. Similarly, in a meta-analysis, Sánchez-Mora et al.\textsuperscript{49} reported that there is no statistically significant effect of the Val66Met polymorphism of the BDNF gene on ADHD subtypes. This finding may indicate that the contribution of BDNF to ADHD is not subtype-specific\textsuperscript{46} or, alternatively, that the small sample sizes of the studies, including our own, have been insufficient to uncover an association.

In our study, the teacher-rated hyperactivity and inattention symptom counts and total scores were higher, and the appropriate behavior scores of the TRF were significantly lower in the GG genotype group than in the A-containing genotype groups. However, the multivariate analysis of variance by assigning the age and gender as covariates have shown that appropriate behavior score of the TRF remained to be statistically significantly lower in GG genotype group of patients with ADHD. As mentioned previously, the GG genotype was observed more frequently in the patients than the controls in the present study, which is consistent with the results of some of the previous studies. Therefore, it may be suggested that the GG genotype may have a role in the pathogenesis of ADHD and may also affect the clinical symptomatology of ADHD. There are few studies that have assessed BDNF polymorphisms and the symptoms related to ADHD. Consistent with our findings, Lee et al.\textsuperscript{22} reported that parents and teachers rate the inattention and hyperactivity/impulsivity scores of ADHD patients with G alleles higher than those of patients with A alleles, but this difference was not statistically significant. Conversely, Gadow et al.\textsuperscript{41} reported that the BDNF Met66- group (A alleles) elicited more severe presence of comorbid ODD in some patients may have created the confounding effects. Additionally, we assessed estimated IQ using only the vocabulary and block design subtests of the WISC-R. Thus, other potential ADHD neuropsychological domains were not assessed (e.g., delay aversion and RT variability). We did not match the ADHD and TD groups in terms of gender although we provided the male predominance in both groups. Finally, we used saliva samples as the DNA source; however, the use of peripheral blood samples could have increased the efficiency of the genotyping.

As a conclusion, in the present study, the GG genotype was
pathogenesis of ADHD. Moreover, the polymorphism of BDNF may influence the clinic features of ADHD. Future studies with larger sample size are needed to clarify the relationship between BDNF Val66Met polymorphism and pathogenesis of ADHD.

REFERENCES

1. Biederman J, Faraone SV. Attention-deficit hyperactivity disorder. Lancet 2005;366:237-248.
2. Faraone SV, Perlis RH, Doyle AE, Smoller JW, Goralnick JJ, Holmgren MA, et al. Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry 2005;57:1313-1323.
3. Banaschewski T, Becker K, Scherag S, Franke B, Coghill D. Molecular genetics of attention-deficit/hyperactivity disorder: an overview. Eur Child Adolesc Psychiatry 2010;19:237-257.
4. Mossner R, Daniel S, Albert D, Heils A, Okladnova O, Schmitt A, et al. Serotonin transporter function is modulated by brain-derived neurotrophic factor (BDNF) but not nerve growth factor (NGF). Neurochem Int 2009;56:197-202.
5. Carvalho A, Caldeira M, Santos S, Duarte C. Role of the brain-derived neurotrophic factor at glutamatergic synapses. Br J Pharmacol 2008;153 (Suppl 1):310-324.
6. Traver S, Marien M, Martin E, Hirsch EC, Michel PP. The phenotypic differentiation of locus ceruleus noradrenergic neurons mediated by brain-derived neurotrophic factor is enhanced by corticotropin releasing factor during the activation of a CAMP-dependent signaling pathway. Mol Pharmacol 2006;70:30-40.
7. Guillén O, Díaz J, Carroll P, Griffon N, Schwartz JC, Sokoloff P. BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization. Nature 2001;411:86-89.
8. Chen SL, Lee SY, Chang YH, Wang TY, Chen SH, Chu CH, et al. The BDNF Val66Met polymorphism and plasma brain-derived neurotrophic factor levels in Han Chinese heroin-dependent patients. Sci Rep 2015;2:8148.
9. Cargill M, Ala-Korpela M, Ireland J, Sklar P, Ardlie K, Patil N, et al. Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet 1999;22:231-238.
10. Chen ZY, Jing D, Bath KG, Ieraci A, Khan T, Siao CJ, et al. Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior. Science 2006;314:140-143.
11. Geller B, Badner JA, Tillman R, Christian SL, Bolhofner K, Cook EH Jr. Linkage disequilibrium of the brain-derived neurotrophic factor Val66Met polymorphism in children with a prepubertal and early adolescent bipolar disorder phenotype. Am J Psychiatry 2004;161:1698-1700.
12. Neves-Pereira M, Cheung JK, Pasdar A, Zhang E, Breen G, Yates P, et al. BDNF gene is a risk factor for schizophrenia in a Scottish population. Mol Psychiatry 2005;10:208-212.
13. Ribasés M, Gratacós M, Armengol L, de Cid R, Badia A, Jiménez L, et al. Met86 in the brain-derived neurotrophic factor (BDNF) precursor is associated with anorexia nervosa restrictive type. Mol Psychiatry 2003;8:745-751.
14. Sen S, Nesse RM, Stoltenberg SE, Li S, Gleberman L, Chakravarti A, et al. A BDNF coding variant is associated with the NEO personality inventory domain neuroticism, a risk factor for depression. Neuropsychopharmacology 2003;28:397-401.
15. Landtme M, Maqdiri P, Squassina A, Kinsky M, Jain U, Macciard F, et al. A potential role for brain-derived neurotrophic factor (BDNF) in adult ADHD. Abstract in J Med Genet Part B 2004;30B:96-97.
16. Kent L, Green E, Hasz Z, Kirley A, Dudbridge F, Lowe N, et al. Association of the paternally transmitted copy of common Valine allele of the Val66Met polymorphism of the brain-derived neurotrophic factor (BDNF) gene with susceptibility to ADHD. Mol Psychiatry 2005;10:939-943.
17. Friedel S, Fontenla Horro E, Wermter AK, Geller F, Dempfle A, Reichwald K, et al. Mutation screen of the brain derived neurotrophic factor gene (BDNF): identification of several genetic variants and association studies in patients with obesity, eating disorders and attention-deficit/hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet 2005;132B:96-99.
18. Brookes K, Xu X, Chen W, Zhou K, Neale B, Lowe N, et al. The analysis of 51 genes in DSM-IV combined type attention deficit hyperactivity disorder: Association signals in DRD4, DAT1 and 16 other genes. Mol Psychiatry 2006;11:934-953.
19. Lee YH, Song GG. BDNF 196 G/A and COMT Val158Met polymorphisms and susceptibility to ADHD: a meta-analysis. J Atten Disord [Epub ahead of print].
20. Hervey AS, Epstein JN, Curry JE. Neuropsychology of adults with attention-deficit/hyperactivity disorder: a meta-analytic review. Neuro psychology 2004;14:485-503.
21. Martinussen R, Hayden J, Hogg-Johnson S, Tannock R. A metaanalysis of working memory impairments in children with attentiondeficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2005;44:377-384.
22. Lee J, Laurin N, Crosbie J, Ickowicz A, Pathare T, Malone M, et al. Association study of the brain derived neurotrophic factor (BDNF) gene in attention deficit hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet 2005;136B:96-101.
23. Rios M, Fan G, Fekete C, Kelly J, Bates B, Kuehn R, et al. Conditional deletion of brain-derived neurotrophic factor in the postnatal brain leads to obesity and hyperactivity. Mol Endocrinol 2001;15:1748-1757.
24. Kipriyanova I, Sandikher J, Schwab S, Hoyer S, Spranger M. Brain derived neurotrophic factor improves long-term potentiation and cognitive functions after transient forebrain ischemia in the rat. Exp Neurol 1999;159:511-519.
25. Mizuno M, Yamada K, Olariu A, Nawa H, Nabeshima T. Involvement of brain-derived neurotrophic factor in spatial memory formation and maintenance in a radial arm maze test in rats. J Neurosci 2000;20:7116-7121.
26. Achenbach TM. Integrative Guide for the CBCL/4-18, YSR, and TRF Profiles. Burlington: Department of Psychiatry, University of Vermont; 1991.
27. Ercan ES, Amado S, Somer O, Çelkoğlu S. [Development of a test battery for the assessment of attention deficit hyperactivity disorder]. Turk J Child Adolesc Ment Health 2001;8:132-144.
28. Göker B, Unal F, Pehlivanburak K, Kütük EG, Akdemir D, Tamer Y. Reliability and validity of schedule for affective disorders and schizophrenia for school age children-present and lifetime version-turkish version (K-SADS-PL-T). Turk J Child Adolesc Ment Health 2004;11:109-116.
29. Leckman JF, Edelhoch S, Thompson D, Belanger A, Weissman MM. Best estimate of lifetime psychiatric diagnosis: a methodological study. Arch Gen Psychiatry 1982;39:879-883.
30. Gualtieri CT, Johnson LG. Age-related cognitive decline in patients with mood disorders. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:962-967.
31. Huang EJ, Reichardt LF. Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci 2001;24:677-736.
32. Pan W, Banks WA, Faeddl MR, Bluth J, Kastin AJ. Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuro-

BDNF Is a Risk Factor for ADHD
33. Ozturk E, Okur H, Eker C, Eker OD, Gümil AS, Akarsu N. The effect of depression, BDNF gene val66met polymorphism and gender on serum BDNF levels. Brain Res Bull 2010;81:61-65.

34. Zhang XY, Chen da C, Xiu MH, Haile CN, Lao X, Xu K, et al. Cognitive and serum BDNF correlates of BDNF Val66Met gene polymorphism in patients with schizophrenia and normal controls. Human Genet 2012;131:1187-1195.

35. Lang UE, Hellweg R, Sander T, Gallinat J. The Met allele of the BDNF Val66Met polymorphism is associated with increased BDNF serum concentrations. Mol Psychiatry 2009;14:120-122.

36. Bus BA, Arias-Vasquez A, Franke B, Prickaerts J, de Graaf J, Voshaar RC. Increase in serum brain-derived neurotrophic factor in met allele carriers of the BDNF Val66Met polymorphism is specific to males. Neuropsychobiology 2012;65:183-187.

37. Aureli A, Del Beato T, Sebastiani P, Marimpietri A, Melliø CV, Sechi E, et al. Attention-deficit hyperactivity disorder and intellectual disability: a study of association with brain-derived neurotrophic factor gene polymorphisms. Int J Immunopathol Pharmacol 2010;23:873-880.

38. Li H, Liu L, Tang Y, Ji N, Yang L, Qian Q, et al. Sex-specific association of brain-derived neurotrophic factor (BDNF) Val66Met polymorphism and plasma BDNF with attention-deficit/hyperactivity disorder in a drug-naïve Han Chinese sample. Psychiatry Res 2014;208:217;191-197.

39. Schimmelmann BG, Friedel S, Demplte A, Wärnke A, Lesch KP, Wältz S, et al. No evidence for preferential transmission of common valine allele of the Val66Met polymorphism of the brain-derived neurotrophic factor gene [BDNF] in ADHD. J Neural Transm (Vienna) 2007;114:523-526.

40. Sanchez-Mora C, Ribasés M, Ramos-Quiroga JA, Casas M, Bosch R, Boreatti-Hümmer A, et al. Meta-analysis of brain-derived neurotrophic factor p.Val66Met in adult ADHD in four European populations. Am J Med Genet B Neuropsychiatry Genet 2010;153B:512-523.

41. Gadow KD, Rooli J, DeVincenzo CJ, Kirsch S, Hatchwell E. Association of COMT (Val158Met) and BDNF (Val66Met) Gene polymorphisms with anxiety, ADHD and tics in children with autism spectrum disorder. J Autism Dev Disord 2009;39:1542-1551.

42. Bergman O, Westberg L, Lichtenstein P, Eriksson E, Larsson H. Study on the possible association of brain-derived neurotrophic factor polymorphism with the developmental course of symptoms of attention deficit and hyperactivity. Int J Neuropsychopharmacol 2011;14:1367-1376.

43. Willoughby MT. Developmental course of ADHD symptomatology during the transition from childhood to adolescence: a review with recommendations. J Child Psychol Psychiatry 2003;44:88-106.

44. Egan M, Koijuma M, Callicott J, Goldberg T, Kolachana B, Bertolino A, et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003;112:257-269.

45. Rybakowski JK, Borkowska A, Czerski PM, Skibinska M, Hauser J. Polymorphism of the brain-derived neurotrophic factor gene and performance on a cognitive prefrontal test in bipolar patients. Bipolar Disord 2003;5:468-472.

46. Hariri AR, Goldberg TE, Mattay VS, Kolachana BS, Callicott JH, Egan MF, et al. Brain-derived neurotrophic factor val66met polymorphism affects memory related hippocampal activity and predicts memory performance. J Neurosci 2003;23:6690-6694.

47. Hashimoto R, Morisaki Y, Yamashita F, Mori T, Nemoto K, Okada T, et al. Dose-dependent effect of the Val66Met polymorphism of the brain-derived neurotrophic factor gene on memory-related hippocampal activity. Neurosci Res 2008;61:360-367.

48. Dennis NA, Cabeza R, Need AC, Waters-Menier S, Goldstein DB, Labar KS. Brain-derived neurotrophic factor val66met polymorphism and hippocampal activity on during episodic encoding and retrieval tasks. Hippocampus 2010;20:980-989.

49. van Wingen G, Rijpkema M, Franke B, vanEijndhoven P, Tendolkar I, Verkes RJ, et al. The brain-derived neurotrophic factor Val66Met polymorphism affects memory formation and retrieval of biologically salient stimuli. Neuroimage 2010;50:1212-1218.